Stocks of Mersana Therapeutics Inc (NASDAQ:MRSN) traded higher last session on Wall Street, down -10.46% to $0.29.
MRSN stock price is now -19.41% away from the 50-day moving average and -73.53% away from the 200-day moving average. The market capitalization of the company currently stands at $36.27M.
, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Mandelia Ashish, VP, Chief Accounting Officer sold 3,554 shares of the company’s stock on Jan 16 ’25. The stock was sold for $2,061 at an average price of $0.58. Upon completion of the transaction, the VP, Chief Accounting Officer now directly owns 57,519 shares in the company, valued at $16680.51. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 16 ’25, Director Protopapas Anna sold 8,637 shares of the business’s stock. A total of $5,009 was realized by selling the stock at an average price of $0.58. This leaves the insider owning 168,041 shares of the company worth $48731.89. A total of 22.30% of the company’s stock is owned by insiders.
During the past 12 months, Mersana Therapeutics Inc has had a low of $0.26 and a high of $2.83. The fifty day moving average price for MRSN is $0.36114 and a two-hundred day moving average price translates $1.09942 for the stock.
The latest earnings results from Mersana Therapeutics Inc (NASDAQ: MRSN) was released for 2025-03-31. The net profit margin was -217.64% and return on equity was -505.14% for MRSN. The company reported revenue of $2.75 million for the quarter, compared to $9.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -70.21 percent.
